Genmab — Februar 2025

[Sukkeralf]

E L - today these patients have alternatives like tec and tal. Then maybe it should be in powerful combinations. Or if all know HexaCD38 works better than Darzalex it could be off label sales in other lines that approved for.

[Sukkeralf]

But we also need sc dosing probably - do Janssen have sc dosing possibilities left at Halozymes?

[lahn1]

“I think the data looks brilliant. I mean, where you would have told me 10 years ago that it is possible to make a more positive antibody than daratumumab, I would have laughed at it because I wouldn't have believed it because daratumumab is a unique antibody, is one of the best therapeutic antibodies developed over the last decades.

[lahn1]

So I think in the industry, 3 years from now, it's going to be 1 of the top 3 biggest cancer drugs on earth. Right now it's the biggest product for JNJ and then to have a better one, which is differentiated. I think it's potentially super exciting.”

[JKY_VH]

lahn1, det understreger vel at hvis ikke JNJ/Genmab udvikler et bedre præparat end Dara, så gør andre det kannibalisering eller ej.

[exitnu]

Genmab (GMAB) Gets a Hold from Morgan Stanley, price target of $31.00 (Feb. 18, 2025, 07:16 AM).

[E_L]

whatever happens, one would expect HexaCD38 to be marketed in combination anyway, no? and if that combo is with Tec or Tal; all the better

[lahn1]

yes Jan eluted to that point. Treatment is al about combination.

[lahn1]

Ja enten disrupter du dig selv eller også disrupter andre dig, period !

[Sukkeralf]

Yes but if Genmab is doing th clinical trials they probably need to buy tec and tal - so its so much easier if Janssen takes the option

[E_L]

it is definitely easier; i think we established that long time ago. And best for the short term share price reaction. And my blood pressure... (whether JNJ would or would not sponsor the Tec or Tal , is really a
minor issue i would think)

[E_L]

New trial - eal-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma / EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL) https://clinicaltrials.gov/study/NCT06830759

[gentogen]

Daratumumab is increasingly used in first-line, and soon patients that relapse while on daratumumab will become a common challenge.

[gentogen]

ScienceDirect

(www.sciencedirect.com)

[ProinvestorNEWS]

Teknisk: Genmab i brud op gennem vigtige modstande, fortsætter op i USA https://proinvestor.com/investornyt/1279889/teknisk-genmab-i-brud-op-gennem-vigtige-modstande-fortsaetter-op-i-usa

[E_L]

Leo Habets
@L_Habets
Daratumumab Seit einiger Zeit behandeln wir Post, COVID, Post Vac und MEC FS Patienten mit Daratumumab wir haben jetzt insgesamt sieben Patienten in der Behandlung https://x.com/L_Habets/status/1891069465686634514 https://x.com/L_Habets/status/1891210734530400443

[bikube]

die Behandlung ist teuer, die kostet 20000€ fyr 4 gaben. Det er vist første gang, jeg har set en kontant pris på Dara.

[E_L]

TipRanks
Feb. 19, 2025, 01:35 AM
In a report released today, Emily Field from Barclays maintained a Buy rating on Genmab A/S
, with a price target of DKK2,100.00.

[E_L]

looks like we will get an Acasunlimab Poster at the European Lung Cancer Congress at the end of the March https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/presentation/list?q=acasunlimab Also a few for amivantamab, also orals

[E_L]

Kempen erhöht Kursziel für Genmab auf DKK 3.070 (2.950) und bekräftigt Kaufen - BN
Am 19. Februar 2025 https://de.marketscreener.com/kurs/aktie/GENMAB-A-S-63733191/news/Kempen-erhoht-Kursziel-fur-Genmab-auf-DKK-3-070-2-950-und-bekraftigt-Kaufen-BN-49100440/